SCR130
SCR130 is a SCR7-based DNA nonhomologous end-joining (NHEJ) inhibitor. SCR130 inhibits the end-joining of DNA in a Ligase IV-dependent manner. SCR130 is specific to Ligase IV, and shows minimal or no effect on Ligase III and Ligase I mediated joining. SCR130 induces cell apoptosis and has anticancer activity[1].
Product Specifications
CAS Number
2377858-38-1
UNSPSC
12352005
Target
Apoptosis; DNA/RNA Synthesis
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/scr130.html
Purity
98.23
Solubility
DMSO : 100 mg/mL (ultrasonic; warming)
Smiles
O=C1NC(NC(C12N=C(CC2C3=CC=C(C=C3)Cl)C4=CC=C(Cl)C=C4)=O)=S
Molecular Formula
C19H13Cl2N3O2S
Molecular Weight
418.30
References & Citations
[1]Ujjayinee Ray, et al. Identification and characterization of novel SCR7-based small-molecule inhibitor of DNA end-joining, SCR130 and its relevance in cancer therapeutics. Mol Carcinog. 2020 Jun;59 (6) :618-628.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
